REPLReplimune, Inc.Running, no new patients
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Merkel Cell Carcinoma · Basal Cell Carcinoma · Locally Advanced Cutaneous Squamous Cell Carcinoma · Cancer
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +3.9
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 1/2
- Patients
- 69 (final count)
- Started
- May 15, 2020
- Main results expected
- Jul 2029
- Fully finished
- Nov 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Primary Objective for Patients with Locally Advances CSCC (laCSCC)
Measured over: 36 months
Primary Efficacy Objective for Patients with Other Skin Cancers
Measured over: 36 months
Primary Safety Objective for Patients with Other Skin Cancers
Measured over: 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04349436 · record last updated 2026-04-22 · checked 2026-11-09 15:42 UTC